

DRUG SAFETY NOTICE

Supply Shortage

DRUG NAME/STRENGTH/Form:

Neostigmine 2.5mg in 1ml / Glycopyrronium bromide
500micrograms in 1ml solution for injection ampoules

PROBLEM

- There is a supply issue with Neostigmine 2.5mg in 1ml / Glycopyrronium bromide 500micrograms in 1ml solution for injection ampoules.
- Date for re-supply is TBC
- It is restricted to theatre use only on the trust formulary.

ACTION

- Do not prescribe the combination product (neostigmine 2.5mg in 1ml / glycopyrronium bromide 500micrograms in 1ml combination injection), as there is currently no more stock available.

ALTERNATIVES

The two drugs are available in separate component unit ampoules in the following strengths:

Neostigmine

- 2.5mg/1ml solution for injection ampoules.

Glycopyrronium bromide

- 200micrograms/1ml solution for injection ampoules
- 600micrograms/3ml solution for injection ampoules

The two drugs must be prescribed and administered separately.

Mixing of the two components is not recommended.

SUPPORTING INFORMATION

Neostigmine with glycopyrronium is used in the reversal of non-depolarising neuromuscular blockade by intravenous injection.

Dose in adults: 1–2 mL, repeated if necessary, alternatively 0.02 mL/kilogram, repeated if necessary; maximum 2 mL per course.

Key Resources

[SmPC Glycopyrronium and Neostigmine Metilsulfate Solution for Injection](#)

[SmPC Neostigmine Methylsulfate Injection BP 2.5mg in 1ml](#)

[SmPC Glycopyrronium Bromide Solution for Injection](#)

[BNF: Neostigmine](#)

[BNF: Glycopyrronium](#)

[Medusa Injectable Medicines Guide](#)

**FOR FURTHER INFORMATION CONTACT YOUR WARD BASED PHARMACY TEAM
OR
THE PHARMACY DEPARTMENT (CITY ext.5263; SANDWELL ext.3783).**

DATE OF ISSUE: 09.09.2024

REFERENCE NUMBER: 01-0924

PATIENTS
PEOPLE
POPULATION

